Yu-Nan Huang

Dr. Yu-Nan Huang

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 August 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
YHYu-Nan Huang
Yu-Nan Huang
WLWen-Ling Liao
Wen-Ling Liao
JHJing‐Yang Huang
Jing‐Yang Huang
YLYu-Jung Lin
Yu-Jung Lin
SYShun‐Fa Yang
Shun‐Fa Yang
PSPen‐Hua Su
Pen‐Hua Su

17 July 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
WLWen-Ling Liao
Wen-Ling Liao
YHYu-Nan Huang
Yu-Nan Huang
YCYa‐Wen Chang
Ya‐Wen Chang
TLTing‐Yuan Liu
Ting‐Yuan Liu
HLHsing‐Fang Lu
Hsing‐Fang Lu
FTFuu‐Jen Tsai
Fuu‐Jen Tsai

Verified
Journal Article
Open access
PDF file
YHYu-Nan Huang
Yu-Nan Huang
SCShang-Lun Chiang
Shang-Lun Chiang
YLYu-Jung Lin
Yu-Jung Lin
SLSu-Ching Liu
Su-Ching Liu
YLYen-Hsien Li
Yen-Hsien Li
CWChung-Hsing Wang
Chung-Hsing Wang
Long non-coding RNA steroid receptor RNA activators (LncRNA SRAs) are implicated in the β-cell destruction of Type 1 diabetes mellitus (T1D), but functional association remains poorly understood. Here, we aimed to verify the role of LncRNA SRA regulation in β-cells. LncRNA SRAs were highly expressed in plasma samples and peripheral blood mononuclear cells (PBMCs) from T1D patients. LncRNA SRA was strongly upregulated by high-glucose treatment. LncRNA SRA acts as a microRNA (miR)-146b sponge through direct sequence–structure interactions. Silencing of lncRNA SRA increased the functional genes of Tregs, resulting in metabolic reprogramming, such as decreased lactate levels, repressed lactate dehydrogenase A (LDHA)/phosphorylated LDHA (pLDHA at Tyr10) expression, decreased reactive oxygen species (ROS) production, increased ATP production, and finally, decreased β-cell apoptosis in vitro. There was a positive association between lactate level and hemoglobin A1c (HbA1c) level in the plasma from patients with T1D. Recombinant human interleukin (IL)-2 treatment repressed lncRNA SRA expression and activity in β-cells. Higher levels of lncRNA-SRA/lactate in the plasma are associated with poor regulation in T1D patients. LncRNA SRA contributed to T1D pathogenesis through the inhibition of miR-146b in β-cells, with activating signaling transduction of interleukin-1 receptor-associated kinase 1 (IRAK1)/LDHA/pLDHA. Taken together, LncRNA SRA plays a critical role in the function of β-cells.

22 June 2022 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
PDF file
CWChung-Hsing Wang
Chung-Hsing Wang
WLWen-Li Lu
Wen-Li Lu
SCShang-Lun Chiang
Shang-Lun Chiang
TTTsung-Hsun Tsai
Tsung-Hsun Tsai
SLSu-Ching Liu
Su-Ching Liu
YHYu-Nan Huang
Yu-Nan Huang
Context Nephropathy is a severe complication of type 1 diabetes (T1DM). However, the interaction between the PDHA1-regulated mechanism and CD4+ T cells in the early stage of kidney tubular injury remains unknown. Objective To evaluate the role of PDHA1 in the regulation of tubular cells and CD4+ T cells and further to study its interaction in tubular cell injury in T1DM. Methods Plasma and total RNA were collected from T cells of T1DM patients (n = 35) and healthy donors (n = 33) and evaluated for neutrophil gelatinase-associated lipocalin (NGAL), kidney injury molecule-1, PDHA1, and biomarkers of CD4+ T cells including T helper 1 cells (Th1) and regulatory T cells (Treg) markers. HK-2 cells cocultured with CD4+ T cells from T1DM patients or healthy donors (HDs) to evaluate the interaction with CD4+ T cells. Results Increased PDHA1 gene expression levels in CD4+ T cells were positively associated with the plasma level of NGAL in T1DM patients and HDs. Our data demonstrated that the Th1/Treg subsets skewed Th1 in T1DM. Knockdown of PDHA1 in kidney tubular cells decreased ATP/ROS production, NAD/NADH ratio, mitochondrial respiration, and cell apoptosis. Furthermore, PDHA1 depletion induced impaired autophagic flux. Coculture of tubular cells and T1DM T cells showed impaired CPT1A, upregulated FASN, and induced kidney injury. Conclusion Our findings indicate that Th1 cells induced tubular cell injury through dysregulated metabolic reprogramming and autophagy, thereby indicating a new therapeutic approach for kidney tubular injury in T1DM.

5 August 2023 in Children
Verified
Journal Article
Open access
PDF file
YHYu-Nan Huang
Yu-Nan Huang
JHJing-Yang Huang
Jing-Yang Huang
CWChung-Hsing Wang
Chung-Hsing Wang
PSPen-Hua Su
Pen-Hua Su
Background: Individuals with Down syndrome are at a higher risk of cardiac, renal, and other health issues due to a complex disease physiology. However, few data exist on long-term disease risks to guide prevention and care. We aimed to determine the 10-year incidence of cardiac, renal, and urinary tract complications in Down syndrome versus matched controls. Methods: This retrospective cohort study utilized a large collaborative database. We identified 32,444 patients with Down syndrome and matched controls, excluding those with pre-follow-up target events. Covariates included demographics, lifestyle factors, and comorbidities. Outcomes were ischemic heart disease, hypertension, hypothyroidism, epilepsy, urinary tract infections and chronic kidney disease. We calculated unadjusted and adjusted hazard ratios (HRs) and 95% confidence intervals (CIs) using Cox regression and plotted Kaplan–Meier survival curves. Findings: Over 10 years, Down syndrome patients showed a 3.7-fold higher ischemic heart disease risk (95% CI: 3.0–4.6) and a 1.6-fold higher hypertension risk (95% CI: 1.4–1.8) versus controls. Hypothyroidism (HR = 2.0; 95% CI: 1.7–2.4), epilepsy (HR = 4.5; 95% CI: 3.5–5.8), and urinary tract infection (HR = 3.9; 95% CI: 3.4–4.6) risks were also higher. Chronic kidney disease risk was 2.7-fold greater (95% CI: 2.1–3.5). Survival analysis confirmed a significantly higher incidence of all outcomes in Down syndrome (p < 0.0001). Interpretation: This large study found major health challenges in Down syndrome, with risks 3- to 5-fold higher for chronic conditions versus matched controls over 10 years. Though survival remains high with proper care, focusing resources on the prevention and management of complications in this high-risk group can optimize well-being across the lifespan. Future research accounting for limitations here would provide definitive estimates of disease risk in Down syndrome to guide targeted health strategies.

12 December 2025 in Advanced Science
Verified
Journal Article
Open access
YHYu-Nan Huang
Yu-Nan Huang
MTMin‐Yu Tsou
Min‐Yu Tsou
PLPin‐Hung Li
Pin‐Hung Li
JCJo‐Ching Chen
Jo‐Ching Chen
Yen-Liang LiuYen-Liang Liu
Yen-Liang Liu
PSPen‐Hua Su
Pen‐Hua Su
Evidence on pre‐transplant metabolic therapy remains limited. We evaluated whether concurrent glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) plus sodium–glucose cotransporter 2 inhibitor (SGLT2i) use before solid‐organ transplantation was associated with post‐transplant outcomes in adults with obesity and type 2 diabetes. A target trial is emulated using de‐identified electronic health records from TriNetX US. Dual therapy is compared with GLP‐1 RA, SGLT2i, and usual care using 1:1 propensity‐score matching. The primary outcome is all‐cause mortality at 12 months; kidney graft failure, rejection, complications, and infections are secondary. Sensitivity analyses included the global network, landmark, extensions at 24 and 36 months. Three matched cohorts are constructed, dual versus GLP‐1 RA (n = 4718 pairs), dual versus SGLT2i (n = 4282), and dual versus usual care (n = 3787). At 12 months, dual therapy is associated with lower mortality versus GLP‐1 RA (hazard ratio [HR] 0.69, 95% confidence interval [CI] 0.57–0.85), SGLT2i (0.59, 0.48–0.72), and usual care (0.52, 0.43–0.64). Infection endpoints are neutral or lower. Estimates are consistent across sensitivity analyses. In transplant candidates with obesity and type 2 diabetes, pre‐transplant GLP‐1 RA+SGLT2i use is associated with lower mortality than monotherapy or usual care. Prospective evaluation is warranted.